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Abstract
Background and purpose: Radiotherapy of central lung tumors carries a higher risk of treatment-related toxicity
and local failure. In the era of aggressive oligometastic management the exploration of the proper dose-
fractionation for metastatic central lung tumors is essential.
Materials and methods: Patients diagnosed with high-risk metastatic lesions of the central pulmonary tree
comprised this single-institutional retrospective analysis. “High-risk” central pulmonary lesions were defined as
those with abutment and/or invasion of the mainstem bronchus. All patients were treated using the CyberKnife
SBRT system in 5 fractions to a total dose of 35 or 40 Gy.
Results: Twenty patients were treated from 2008 to 2011 at Georgetown University Hospital. At a median follow up of
19 months, 1-year Kaplan-Meier local control and overall survival was 70 and 75 %, respectively. Late grade 2 or higher
atelectasis was the most common treatment-related toxicity and was significantly associated with maximum dose to
the mainstem bronchus. Gross endobronchial involvement was associated with significantly lower overall survival.
Conclusions: Five-fraction SBRT to a total dose of 35 or 40 Gy appears to be a safe and effective management strategy
for high-risk central pulmonary metastatic lesions, though care should be taken to limit the maximum point dose to
the mainstem bronchus.
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Introduction
Management of symptomatic and/or compromising pul-
monary metastases is a common clinical scenario encoun-
tered by oncologists. Although first-line treatment of
metastatic disease is often systemic therapy there is a mod-
ern movement to more aggressively manage oligometa-
static disease with local therapy [1, 2]. Long-term survival
in carefully selected metastatic patients was initially estab-
lished by the International Registry of Lung Metastases
trial where surgical metastasectomy achieved a 26 % 10-
year overall survival rate [3]. Central lung metastases are a
particularly dangerous variant of pulmonary metastases
and not only limit a patient’s life expectancy but can also
profoundly impact their quality of life [4]. Unfortunately,
treatment of these central lung tumors with high dose radi-
ation carries an increased risk of treatment-related toxicity
relative to more peripheral lung lesions [5, 6].
The elevated risk of toxicity with SBRT to central pri-
mary lung tumors has been previously demonstrated in
the analysis of the prospective phase II trial for early
stage inoperable non-small cell lung cancer (NSCLC)
published by Timmerman et al. [5]. The reported toxic-
ities included decline in PFTs, pneumonia, and pleural/
pericardial effusions. Such toxicities are reflective of the
high doses delivered to the proximal bronchial tree caus-
ing secondary atelectasis and nearby radiosensitive struc-
tures such as the esophagus, heart, and spinal cord [5, 7,
8]. The increased toxicity associated with centrally lo-
cated tumors is the focus of the current prospective
RTOG 0813 and EORTC 22113-0813 Lungtech trials,
which were developed to identify a safe and effective
dose-fractionation schedule for centrally located early
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stage NSCLC [9]. Although the high doses used for early
stage lung cancer SBRT not surprisingly achieve high
local control rates, the risk of toxicity is arguably un-
acceptable in the metastatic patient population [10]. The
balance in the metastatic cohort must still shift in favor
of toxicity minimization until prospective evidence sup-
porting a survival benefit exists, which can warrant the
increased side effect profile. This is especially true for
those patients with high-risk central lung metastases
where toxicity may be even more significant.
Many analyses of centrally located tumors treated
with SBRT have defined “central” tumors as within
2 cm of the mainstem bronchus or other mediastinal
structures [5–7, 11]. This is the most common defin-
ition utilized, which was initially defined by Timmer-
man et al. and is currently employed in RTOG 0813
[5]. Nevertheless, within this group exists an even
more dangerous variant with actual tumor involve-
ment of the mainstem bronchus. In fact, these tu-
mors were deemed so dangerous that the EORTC
22113-0813 Lungtech trial excluded definitive SBRT
of tumors with invasion of the proximal bronchial
tree and/or hilar structures [9]. A recent 18 patient
cohort analyzed by Haseltine et al. noted signifi-
cantly higher SBRT-related toxicity and death in
those patients with tumors abutting the proximal
bronchial tree [12]. Alternatively, Stanford reported a
smaller cohort of 7 patients with “ultra-central” tu-
mors directly abutting the proximal bronchial tree or
trachea and found no significant difference in 2-year
overall survival, local control, or treatment-related
toxicities relative to other central and peripheral
lung lesions [13]. As systemic therapy options con-
tinue to improve there is a potential for longer-term
survival in the metastatic patient population, which
may be augmented further by the radiotherapeutic
ablation of larger tumor sites [1, 14]. In this retro-
spective analysis we investigate the clinical outcomes
of 20 patients diagnosed with advanced “high-risk”
metastatic tumors with actual abutment or invasion




The MedStar Health Research Institute Georgetown
University Oncology Institutional Review Board, ap-
proved this retrospective analysis of an established de-
partmental treatment approach. Twenty consecutive
patients with inoperable metastatic lung lesions localized to
the central pulmonary tree were treated in 5 fractions with
the SBRT CyberKnife radiosurgical system. The majority of
metastatic lung lesions were confirmed pathologically prior
to treatment when clinically prudent. Prudence was
assessed by the interventional pulmonologist and included
the accessibility of the lesion (including the safety of said bi-
opsy), performance status of the patient, and/or lack of pre-
vious pathologic confirmation of metastatic disease. High-
risk central lung lesions were defined as those abutting
and/or invading the left or right mainstem bronchus [15].
All patients were evaluated by the same pulmonologist
prior to treatment (EDA). Treatment with the CyberKnife
SBRT system required the placement of 3 to 5 non-
collinear fiducials within or directly adjacent to the tumor
for tracking purposes [15, 16]. All patients underwent bron-
choscopic placement of fiducials by the same pulmonologist
(EDA). Patients with primary localized lung cancers or
those with previous in-field thoracic irradiation were ex-
cluded from this study.
Treatment planning and delivery
A fine-cut treatment planning CT scan was obtained in
the supine treatment position for each patient using a
GE LightSpeed RT16. CT scans were obtained with
intravenous and/or oral contrast when clinically feasible
and during full inhalation. Additional imaging including
PET/CT scan was obtained as clinically indicated at the
discretion of the treating physician (BCT). Gross tumor
volumes (GTV) were contoured often with input from
the attending pulmonologist. A 5 mm expansion from
GTV to planning target volume (PTV) was added at the
discretion of the attending radiation oncologist (BCT). A
treatment plan was generated using the MultiPlan 5.2.1
non-isocentric inverse-planning algorithm. Radiation
was delivered in 5 equal fractions of 7 or 8 Gy pre-
scribed to an isodose line that covered at least 95 % of
the PTV. Patients were treated in the supine position
with their arms at their sides. Treatment was delivered
over 5 consecutive days. Of note, treatment duration
was calculated as the number of days from first to last
treatment fraction.
The Synchrony Respiratory Motion Tracking System
was utilized for both inter- and intrafraction tracking to
accommodate for patient-specific respiratory motion. In
this system, surface respiratory motion is monitored with
external light-emitting markers attached to a patient-vest
that is worn during treatment. These external markers are
continuously monitored during treatment with a camera
array and correlated with the internally placed fiducial
markers tracked during treatment with orthogonal x-rays.
In effect, an adaptive respiratory model is created during
treatment for tumor position verification [15].
Follow-up
Patients were followed with physical examination and
CT+/−PET imaging at 3 to 6 month intervals per routine
institutional practice. Palliative response was evaluated
with a combination of radiation oncology, pulmonology,
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and medical oncology follow up documentation. Local
tumor recurrence was defined as tumor progression
evaluated on follow up radiological imaging. Local
tumor progression was based on official radiological
review and included increased tumor size, contrast en-
hancement, and/or mass effect. Overall survival and
local control were measured from the date of treat-
ment completion to the date of patient death and
radiological progression or death, respectively. Toxic-
ities were scored according to the National Cancer In-
stitute Common Terminology Criteria for Adverse
Events, Version 3.0 with acute and late toxicities sepa-
rated at day 90.
Statistical analysis
Statistical analysis was performed with the IBM SPSS
Statistics version 22 (IBM Corporation and other(s)
1989, 2013). Dosimetric toxicity analysis was per-
formed utilizing the Student’s t-Test (single-tailed,
equal variance distribution). Actuarial local control




Twenty patients with a median age of 66 years (range,
24 to 82 years) were treated from November 2008 to
November 2011 at Georgetown University Hospital.
The gender distribution was equal and the median pre-
treatment ECOG performance status was 0. Distribu-
tion of metastatic histologies included the following: 7
adenocarcinoma, 4 squamous cell carcinoma, 3 renal
cell carcinoma, 2 carcinoid, 2 sarcoma (Ewing’s and
leiomyosarcoma), 1 adenoid cystic, and 1 hepatocellu-
lar. The location of the primary tumors included the
following: 7 pulmonary, 4 gastrointestinal, 3 head and
neck, 3 pelvic, and 3 genitourinary. Isolated intratho-
racic disease was noted in of 35 % of patients, and add-
itional extrathoracic metastatic disease was present in
the remaining 65 %. Pre-radiotherapy ipsilateral thor-
acic surgery and chemotherapy was noted in 60 and
75 % of patients, respectively. Specific patient charac-
teristics are shown in Table 1.
Treatment characteristics
Patients were treated using the CyberKnife SBRT system
to a median total dose of 40 Gy (35 or 40 Gy) all in 5
fractions, which corresponded to a biologic equivalent
dose (BED10) of 59.5 and 72 Gy, respectively. Treatment
was delivered to a median prescription isodose line of
75.5 % with median GTV target coverage of 98 % and
average conformality index of 1.53. Mean tumor volume
treated (PTV) was 111.3 cc (range, 22.6 to 300.0 cc) and
median tumor volume treated was 85.8 cc. Treatment
plans were composed of hundreds of pencil beams deliv-
ered using a single 20 to 40 mm diameter collimator.
Median treatment duration from start to completion of
SBRT was 7 days (range, 5 to 8 days). Mean maximum
point doses delivered to the mainstem bronchus and
esophagus were 46.7 and 28.7 Gy, respectively. Mean
maximum point doses delivered to the spinal cord and
left ventricle were 12.7 and 14.9 Gy, respectively. Mean
and median total lung V15 Gy was measured to be 399.4
and 312.5 cc, respectively. Specific treatment and dosi-
metric characteristics are shown in Table 2.
Table 1 Patient characteristics
Characteristic No. patients (%)
Age
< 60 8 (40)
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Palliative response
Fourteen patients had documented symptomatic central
pulmonary metastases prior to treatment. The remaining
patients were asymptomatic but were treated due to the
compromising location and singular progression of the
metastatic lesion. Pretreatment symptoms included short-
ness of breath (55 %), cough (45 %), and/or hemoptysis
(15 %) as seen in Table 1. Nine patients (64 %) who were
symptomatic prior to radiotherapy received moderate
to significant symptomatic palliation after SBRT treat-
ment. In the 5 symptomatic patients who received no
palliation 2 developed late radiation toxicity, 1 devel-
oped progressive non-local symptomatic thoracic dis-
ease, and 1 failed locally.
Treatment toxicity
Acute grade 2 or higher toxicity was noted in 1 patient
who developed medically manageable esophagitis (grade
2). Documented late grade 2 or higher radiation toxicity
was observed in 30 % of treated patients and included
the following: grade 2 atelectasis (3), grade 2 bronchitis
(1), grade 3 pneumonitis (1), and grade 4 atelectasis (1).
Interestingly, all 5 late toxicities occurred in patients with
right-sided tumors. Atelectasis was the most common late
toxicity observed. One patient of the 5 who did not
undergo pre-SBRT chemotherapy developed late grade 4
atelectasis. The remaining four grade 2 or higher late toxic-
ities occurred in those patients who received pre-treatment
chemotherapy (33 % of the chemotherapy cohort). Dosi-
metric univariate analysis of the cohorts who did and did
not develop late atelectasis revealed prescription dose (p =
0.031), maximum point dose (51.9 vs. 47.4 Gy, p = 0.031),
and major bronchus maximum point dose (49.0 vs.
46.1 Gy, p = 0.029) to be the only statistically significant
predictors of late grade 2 or higher atelectasis. The one
case of grade 4 atelectasis resulted in complete collapse of
the ipsilateral lung requiring urgent bronchoscopic inter-
vention. Specific late toxicity data is shown in Table 3.
Local control and overall survival
At a median follow up of 19 months, the 1- and 2-year
Kaplan-Meier local control was 70.1 and 57.4 %, respect-
ively (Fig. 1). The median Kaplan-Meier local control was
estimated to be 27.9 months. The 1- and 2-year Kaplan-
Meier overall survival was 75 and 40 %, respectively (Fig. 2).
The median Kaplan-Meier overall survival was estimated to
be 16.3 months. There was no significant difference in local
control duration between 35 and 40 Gy fractionation sched-
ules (17.2 vs. 20.7 months, p= 0.36) or size less or greater
than median PTV of 85.8 cc (21.1 vs. 17.5 months, p= 0.35).
However, there was a trend towards decreased local control
in the GI versus non-GI primaries (8.5 vs. 22.0 months, p=
0.12). The majority of patients (11) died of progressive extra-
thoracic metastatic disease following radiotherapy treatment.
Six patients died of progressive intrathoracic disease and 3
patients were still alive at the time of analysis. Of note, 3 pa-
tients were documented to have invasive endobronchial le-
sions prior to treatment and this very small cohort exhibited
a significant decrease in median overall survival (4.8 vs.
19.8 months, p= 0.029), as seen in Fig. 3, and a trend in de-
creased local control (4.49 vs. 21.9 months, p= 0.085). Figure
4 illustrates a bronchoscopic view of one such invasive endo-
bronchial lesion prior to SBRT.
Discussion
Metastatic lesions of the central pulmonary tree nega-
tively impact a patient’s quality of life and present com-
plex radiobiological challenges for the treating radiation
oncologist. Given their sensitive location these lesions
can provoke severe cough, shortness of breath, and/or
hemoptysis. Although chemotherapy is typically first-line
treatment for metastatic disease it is unlikely to provide
durable local control for such lung metastases [4].
Radiotherapy offers a very effective treatment option for
both palliation and local control. SBRT has emerged as
Table 2 Treatment and dosimetric characteristics
Characteristic No. patients (%) Characteristic No. patients (%)
Prior thoracic surgery Prescription dose (Gy)
Yes 12 (60) 35 8 (40)
No 8 (40) 40 12 (60)
Prior chemotherapy Max point dose (Gy)
Yes 15 (75) Mean 48.3
No 5 (25) Median 46.7
PTV volume (cc) Range 41.7–57.1
Mean 111.3 Major bronchus max dose (Gy)
Median 85.8 Mean 46.7
Range 22.6–300.0 Median 46.4
Conformality index Range 40.0–50.0
Mean 1.53 Esophagus max dose (Gy)
Median 1.50 Mean 28.7
Range 1.21–1.93 Median 31.1
Rx isodose line (%) Range 10.8–40.6
Mean 75.5 Spinal cord max dose (Gy)
Median 75.2 Mean 12.7
Range 70.0–80.0 Median 13.7
PTV coverage (%) Range 3.2–19.3
Mean 98.0 Left ventricle max dose (Gy)
Median 98.0 Mean 14.9
Range 96–100 Range 5.1–37.3
Treatment length Days Total lung V15 Gy (cc)
Median 7 Mean 399.4
Range 5–8 Range 145.0–1005.0
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an ideal treatment modality given the excellent local
control rates observed in the definitive treatment of
early stage inoperable NSCLC [10]. Particularly import-
ant in the metastatic setting, SBRT offers a shorter treat-
ment length yielding a minimal break if any of systemic
therapy, which is still the backbone of treatment for the
metastatic patient. SBRT for lung metastases has been
previously shown to yield effective local control with
minimal toxicity [17]. Nevertheless, Timmerman et al.
reported higher rates of treatment-related toxicity in
central relative to peripheral primary NSCLC tumors in
the definitive setting [5]. Moreover, Baumann et al. dem-
onstrated inferior rates of local control in central relative
to peripheral tumors [18]. Conversely, recent accumulat-
ing retrospective data of admittedly heterogeneous dose
and fractionation schedules seems to indicate the danger
of irradiation to this central region may not have as
clinically significant an impact as previously postulated
Table 3 Specific late treatment toxicity
Histology Primary location Side PTV (cc) Rx dose (Gy) Maximum point dose (Gy) Major bronchus max dose (Gy) Late toxicity
Squamous cell Pulmonary R 79.0 35 46.7 46.7 Grade 3 pneumonitis
Carcinoid Pulmonary R 95.0 35 46.1 46.1 Grade 2 atelectasis
Squamous cell Head & neck R 112 40 52.0 50.0 Grade 2 atelectasis
Adenocarcinoma Uterine R 63.0 40 52.6 50.0 Grade 2 atelectasis
Carcinoid Pulmonary R 126 40 57.1 50.0 Grade 4 atelectasis




















Fig. 1 Kaplan-Meier local control from time of completion of SBRT
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[13, 19–21]. Broadly speaking treatment-related toxic-
ities can be seen in several anatomic locations including:
mainstem bronchus, lung parenchyma, esophagus, bra-
chial plexus and vagus nerve, and chest wall [8]. Many
of these toxicities can be limited by placing dosimetric
constraints on adjacent organs, however central tumors
are often intricately involved with mainstem bronchi
making achieving these constraints more difficult.
A European analysis of factors contributing to the effi-
cacy of SBRT for inoperable stage I NSCLC found that
central lung tumors were both more likely to fail locally
and to develop atelectasis as a treatment-related toxicity
[18]. Likewise, the most common late toxicity observed
in our patient population was atelectasis. Interestingly,
Joyner et al. reported major airway wall thickening evi-
dent on follow up CT scans as a common observation in
their cohort of central lung tumors treated with SBRT
[11]. Although the pathophysiology of this atelectasis is
not firmly established in the literature, it is hypothesized
to be secondary to dose-dependent radiation-induced
damage of the bronchial wall [8]. This dose-dependence
is consistent with our observation of maximum point
dose to the major bronchus as the most significant pre-
dictor of late grade 2 or higher atelectasis. Given the
hypothesized etiology of bronchial wall damage it may
be prudent to consider the major bronchus as a serial
organ at risk and make concerted efforts to avoid hot
spot placement in this region. As toxicity and radio-
logical data accumulates an evolution in our under-
standing of the bronchial wall as a dose limiting
structure is paramount.
It is important to note that not all central pulmonary
lesions are created equally. Hamamoto et al. demon-
strated that metastatic lung lesions rather than NSCLC
primary lesions tend to have higher rates of local recur-
rence [22]. Additionally, Milano et al. reported lower
rates of local control in pulmonary metastases of gastro-





















Fig. 2 Kaplan-Meier overall survival from time of completion of SBRT
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outcomes of 5-fraction SBRT to a higher total dose
(50 Gy) for treatment of oligometastatic thoracic dis-
ease and found all 5 patients with local failures were
those with colorectal primaries [24]. Although, in the
present study there was no significant difference in
duration of local control or overall survival between
metastases of GI and non-GI origin (p = 0.12 and p =
0.23, respectively), there was a trend towards in-
creased local progression in the GI subset. Conse-
quently, it is crucial to note that tumors with lower
α/β may necessitate altered fractionation schemes to
achieve durable local control.
In a similar study, Oshiro et al. reported their single
institutional experience in a retrospective review of 21
patients who all received linac-based SBRT to the pul-
monary hilum [7]. In this study, both metastatic and
primary hilar lung tumors were treated to a median dose
of 50 Gy in 5 fractions (range of 25 to 60 Gy in 1 to 13
fractions). Hilar metastases in this study were defined as
Fig. 4 Bronchoscopic pre-radiotherapy image of a patient with gross




















Endobronchial lesions Non-endobronchial lesions
Fig. 3 Kaplan-Meier overall survival from time of completion of SBRT of those patients with and without gross endobronchial involvement
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within 2 cm of the mainstem bronchus. Reported local
control rates of 74.3 and 59.6 % were observed at 1 and
2 years, respectively. There were no reported grade 2 or
above acute toxicities. Observed late grade 3 or above
toxicities included 1 chronic dyspnea requiring supple-
mental oxygen, 1 recurrent bronchial obstruction caus-
ing intractable cough, and 1 fatal hemoptysis. Of note,
the one reported fatal hemoptysis occurred in a patient
who was previously treated twice with thoracic radiation.
Notwithstanding the fact that tumors in our study were
intricately involved with the central airway rather than
just within 2 cm, reported grade 3 or higher late toxic-
ities were less frequent. Additionally, the 12-month local
control rate of 74.3 % is similar to that reported in our
study (70.1 %) despite the lower median dose delivered
to our cohort.
Our 2-year local control rate of 57.4 % is notably inferior
when compared broadly with that seen in SBRT-treated
central tumors elsewhere in the literature (64 to 95 %)
[21]. This is likely a reflection of the following factors: (1)
SBRT treatment of metastatic pulmonary lesions demon-
strates inferior local control relative to primary NSCLC,
(2) the high-risk nature of these tumors in comparison to
standard-risk or RTOG defined central tumors, and (3)
the lower BED employed in their treatment [9, 21, 22, 25].
Total BED may be the root cause of this inferior local con-
trol. A very large (613 patient) retrospective German ana-
lysis of centrally located stage I NSCLC found significantly
lower BEDs were used to treat central versus peripheral
tumors (72.0 versus 84.4 Gy, respectively) and this
resulted in a notably lower 3-year freedom from local pro-
gression rate (52 versus 84 %, respectively) [25]. There is
an indication from a small 7 patient Stanford cohort of “ultra-
central” tumors that these high-risk lesions may be success-
fully treatedwith higher doses (median 12.5Gy × 4) to achieve
excellent 2-year local control of 100 % without significant in-
crease in toxicity [13]. Of note, 6 of the 7 ultra-central tumors
were of primary rather than metastatic histology and would
be expected to have higher local control rates compared to
metastatic lesions. Overall, data regarding the safety and effi-
cacy of SBRT to high-risk central tumors is scant, and add-
itional research is essential to determine if dose escalation is
safe and can achieve superior local control.
As our understanding of the optimal SBRT treatment
for central pulmonary lesions evolves, recent data sug-
gests treatment of these lesions may not be as dangerous
as previously suspected. Mangona et al. reported the re-
sults of a propensity score matched-pair analysis of 158
central and peripheral lung tumors (primary or meta-
static) treated with SBRT (range of 48 to 60 Gy in 4 to 5
fractions) [19]. Central tumors were defined as within
2 cm of the proximal bronchial tree or PTV touching
the mediastinum. Interestingly, there was no observed
significant difference in any 2-year reported adverse
event based on tumor location. Moreover, the 2-year
incidence of grade 4 and 5 adverse events was exceed-
ingly low at <1 and 0 %, respectively. Park et al. retro-
spectively investigated a cohort of 251 patients with
similarly defined central NSCLC primary tumors treated
with SBRT [20]. Although patients in the central lesion
cohort had significantly larger tumors and were of older
age, multivariate analysis found central tumor location
was not associated with inferior toxicity, local control, or
overall survival. Finally, Davis et al. published a 111
patient cohort with central primary or metastatic lung
tumors treated with SBRT and found no grade 3 or
higher acute or late toxicities [21]. Nevertheless, they
did report a lower 2-year rate of local control in meta-
static versus primary lung lesions (69.8 versus 76.4 %) as
would be expected. Additional prospective data with
appreciable follow-up will be necessary to confirm if
these intriguing modern retrospective reports of minimal
SBRT-related toxicity are reproducible.
Endobronchial lesions may represent the highest of
high-risk pulmonary metastatic lesions. Survival after
diagnosis of endobronchial tumors is generally poor and
in our admittedly very small cohort these lesions were
shown to have significantly lower overall survival relative
to non-endobronchial high-risk central lesions [26].
Overall, diagnosis of endobronchial metastatic tumors is
quite rare with autopsy series reporting a 2 % incidence
in solid malignancies [27]. These lesions are most com-
monly secondary to lung cancers, but can also arise from
metastatic breast, colon, or renal cell carcinoma [26–28].
Much of the literature surrounding management and clin-
ical outcomes of endobronchial lesions is limited to case
reports and retrospective reviews of small cohorts. There
is some data to suggest these lesions respond poorly to
systemic therapy and can lead to meager median
survivals as low as 9 months [29]. Nevertheless, these
lesions tend to be quite symptomatic prior to treatment
and significant mitigation of symptoms can be achieved
with local therapy [29].
Our study reports the efficacy of a 5-fraction SBRT
treatment regimen for high-risk central pulmonary me-
tastases. Of the patients who had symptomatic lesions
prior to treatment the majority (64 %) had effective miti-
gation of their symptoms. Relatively durable tumor con-
trol was observed with a 12-month local control of
70.1 %, which translated into a 1-year overall survival of
75 %. Late grade 2 or higher atelectasis was the most
common treatment-related toxicity and correlated sig-
nificantly with a increased maximum point dose to the
major bronchus. Furthermore, those patients with inva-
sive endobronchial lesions demonstrated a significantly
lower overall survival and a trend towards shorter local
control. Limitations of the present study include the
small patient population, the heterogeneity of metastatic
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histologies, and its retrospective analysis. As evidence
accumulates regarding the lower than expected toxicity
of SBRT treatment of central lung tumors the investiga-
tion of dose escalation for these high-risk lesions seems
warranted in attempt to achieve superior local control
closer to that seen in standard-risk central lung tumors.
Reports from the RTOG 0813 and EORTC 22113-0813
Lungtech trials exploring the proper SBRT fractionation
schedule for central primary lung tumors may be extrap-
olated to help address the optimal fractionation schedule
for precarious central pulmonary metastatic lesions.
Conclusion
Five-fraction SBRT to a total dose of 35 or 40 Gy appears
to be a safe and effective management strategy for high-
risk metastatic lesions of the central pulmonary tree. Care
should be taken to limit the maximum point dose to the
mainstem bronchus to avoid late radiation-related toxicity.
The role of radiotherapy in the treatment of these precar-
ious central pulmonary lesions requires further prospect-
ive exploration to establish the efficacy, safety, and proper
fractionation schedule.
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